FIELD: medicine, oncology.
SUBSTANCE: invention elates to treatment of tumors. Method involves administration of aplidine in the dose not exceeding the recommended dose and limiting by the toxicity of the preparation in patient and in the correspondence of one the following schedule: 24 h infusion, once time per a week for 3 weeks and with the following one resting week; 24 h infusion, once time per two weeks; 1 h infusion, once per a week for 3 weeks in each 4 weeks; 1 h infusion, once per a day for 5 days for 3 weeks; 3 h infusion by each the second week. Applying indicated regimens enhances the effectiveness of treatment of malignant tumors being among them with resistance to the conventional treatment and in combination with the absence of the therapy toxicity.
EFFECT: improved and enhanced effectiveness of treatment.
4 cl, 15 dwg, 18 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINED APPLICATION OF ECTEINASCIDIN-743 AND PLATINUM-CONTAINING ANTI-TUMOUR COMPOUNDS | 2004 |
|
RU2391101C2 |
IMPROVED SCHEME OF USING ANTITUMOR COMPOUND IN CANCER THERAPY | 2002 |
|
RU2306933C2 |
COMPOSITION AND UTILIZATION OF ET743 FOR MALIGNANT TUMOR TREATMENT | 2000 |
|
RU2266734C2 |
KAHALALIDE F | 2001 |
|
RU2292216C2 |
COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
APPLICATIONS OF IMMUNOCONJUGATES, THE TARGET OF WHICH IS CD138 | 2012 |
|
RU2632108C2 |
APLIDINE FOR TREATMENT OF MYELOMA | 2004 |
|
RU2335294C2 |
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2014 |
|
RU2678700C2 |
ADVANCED TREATMENT OF TUMOURS | 2004 |
|
RU2341283C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
Authors
Dates
2005-09-27—Published
2000-11-15—Filed